Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: To determine if certain non‐steroidal anti‐inflammatory drugs (NSAIDs) are associated with increased risk of cardiovascular events: acute myocardial infarction (AMI), stroke, and death from coronary heart disease (CHD). Methods: We conducted a retrospective cohort study of Tennessee Medicaid enrollees aged 35–94 years between 1 January 1999 and 31 December 2005. Eligible persons were non‐institutionalized, had continuous enrollment, and had no serious illness prior to cohort entry. Exposure to celecoxib, rofecoxib, valdecoxib, ibuprofen, naproxen, diclofenac, and indomethacin was studied. The outcome was hospitalization for AMI, stroke, or death from CHD among those with and without a history of cardiovascular disease (CVD). Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) are reported. Results: There were 610 001 persons in the final cohort and 14% had a baseline history of CVD. In those without CVD (N = 525 249) there were 1 566 678 person‐years of follow‐up and 12 184 events. In this group, non‐users had 7.90 events/1000 person‐years. Events/1000 person‐years were 10.41 for current use of celecoxib (aHR 1.00, 95% CI 0.89–1.13), 10.91 for rofecoxib (aHR 1.21, 95% CI 1.07–1.37), 12.46 for valdecoxib (aHR 1.30 95% CI 1.04–1.61), and 13.25 for indomethacin (aHR 1.36, 95% CI 1.11–1.66) compared to non‐users. Among patients with a past history of CVD (N = 84 752) there were 397 977 person‐years of follow‐up and 10 248 events. Non‐users had 28.30 events/1000 person‐years. Among those with CVD, rofecoxib use was associated with increased event rate (30.28 events/1000 person‐years [aHR 1.21, 95% CI 1.08–1.37]) and naproxen was associated with a decreased event rate (22.66 events/1000 person‐years [aHR 0.88, 95% CI 0.79–0.99]). Among new users, the results were similar except risk among naproxen users was no longer different than non‐users. Conclusions: We found an increased risk of cardiovascular events among all and new current users of rofecoxib, valdecoxib, and indomethacin in patients with no history of CVD. Among patients with CVD, all and new current rofecoxib use was associated with an increased risk of a cardiovascular event. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“Median (25%, 75%) 3 (1, 6) 7 (3, 11) 6 (3, 11) 8 (4, 13) 5 (2, 9) 5 (2, 9) 5 (2, 10) 6 (3, 11)”
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Assessing the sensitivity of regression results to unmeasured confounders in observational studies
Lin, D. Y., Psaty, B. M., & Kronmal, R. A. (1998) · Biometrics · doi:10.2307/2533848 · Cited by 742
Assessment and Control for Confounding by Indication in Observational Studies
Psaty, B. M., Koepsell, T. D., Lin, D., Weiss, N. S., Siscovick, D. S., Rosendaal, F. R., Pahor, M., & Furberg, C. D. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01603.x · Cited by 363 · cited 1×
“41 Disease risk scorez Median (25%, 75%) 5 (2, 8) 6 (3, 8) 5 (2, 8) 5 (2, 8) 5 (2, 7) 5 (2, 7) 5 (3, 8) 4 (2, 7) Prescriptions Median (25%, 75%) 12 (8, 18) 20 (15, 26) 19 (14, 26) 22 (16, 30) 17 (12, 23) 17 (12, 23) 17 (12, 24) 20 (15, 27) Outpatient visits Median (25%, 75%) 7 (3, 11) 10 (5, 15) 10 (5, 15) 11 (6, 16)…”
Initiation of Antihypertensive Treatment During Nonsteroidal Anti-inflammatory Drug Therapy
Gurwitz, J. H. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520100043031 · Cited by 220
Cited by
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Chan, C.-W., & Peng, P. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01089.x · Cited by 452
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. population
Zhou, Y., Boudreau, D. M., & Freedman, A. N. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3463 · Cited by 304
A basic study design for expedited safety signal evaluation based on electronic healthcare data
Schneeweiss, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1926 · Cited by 255
Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1302 · Cited by 68
Metadata
- Authors
- Roumie, C. L., Choma, N. N., Kaltenbach, L., Mitchel, Jr., Arbogast, P. G., & Griffin, M. R.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2009-07-27
- Volume
- 18
- Issue
- 11
- Pages
- 1053-1063
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2076263459
- Cited by
- 65
- References
- 5
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.